Back to results
US 2022/0025050 A1Published application
Bifunctional molecule directed against human pd-1
AssigneeOse Immunotherapeutics
InventorsNICOLAS POIRIER, CAROLINE MARY, VIRGINIE THEPENIER, AURORE MORELLO
Life of this patent
Estimating the term…
Abstract
The present invention provides a bifunctional molecule comprising a humanized anti-hPD-1 antibody or antigen binding fragment thereof linked to an immunotherapeutic agent able to specifically enhance the immune response and uses thereof.
Claims24
1-24. (canceled)
A bifunctional molecule consisting of:
- (a) a humanized anti-human PD-1 antibody or antigen-binding fragment thereof, which comprises:
- (i) a heavy chain variable domain (VH) comprising HCDR1, HCDR2 and HCDR3, and
- (ii) a light chain variable domain (VL) comprising LCDR1, LCDR2 and LCDR3,
- wherein:
- the heavy chain CDR1 (HCDR1) comprises or consists of an amino acid sequence of SEQ ID NO:
- 1;
- the heavy chain CDR2 (HCDR2) comprises or consists of an amino acid sequence of SEQ ID NO:
- 2;
- the heavy chain CDR3 (HCDR3) comprises or consists of an amino acid sequence of SEQ ID NO:
- 3 wherein X1 is D or E and X2 is selected from the group consisting of T, H, A, Y, N, E and S;
- the light chain CDR1 (LCDR1) comprises or consists of an amino acid sequence of SEQ ID NO:
- 12 wherein X is G or T;
- the light chain CDR2 (LCDR2) comprises or consists of an amino acid sequence of SEQ ID NO:
- 15,
- the light chain CDR3 (LCDR3) comprises or consists of an amino acid sequence of SEQ ID NO:16,
- and
- (b) an immunotherapeutic agent or a fragment thereof,
- wherein the C-terminal end of the heavy and/or light chain(s) of the antibody or antigen-binding fragment thereof is covalently linked to the N-terminal end of the immunotherapeutic agent as a fusion protein, optionally by a peptide linker.
15 more elements
Dependencies are inferred from the claim text.